Kamada (KMDA) Net Income towards Common Stockholders Growth (5y) (2017 - 2026)
Powered by 
Analysis
Kamada (KMDA) Net Income towards Common Stockholders Growth (5y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 64.00% |
| Mar 31, 2026 | 19.87% |
| Dec 31, 2025 | 29.38% |
| Sep 30, 2025 | 1.71% |
| Jun 30, 2025 | 3.62% |
| Mar 31, 2025 | 12.16% |
| Dec 31, 2024 | -27.02% |
| Sep 30, 2024 | -7.09% |
| Jun 30, 2024 | -5.82% |
| Mar 31, 2024 | -12.58% |
| Dec 31, 2023 | -22.41% |
| Sep 30, 2023 | 27.34% |
| Jun 30, 2023 | -20.44% |
| Mar 31, 2023 | -28.03% |
| Dec 31, 2022 | -13.98% |
| Sep 30, 2022 | -5.70% |
| Jun 30, 2022 | -23.05% |
| Mar 31, 2022 | 14.40% |
| Dec 31, 2021 | -20.87% |
| Sep 30, 2021 | 29.71% |